| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Enanta Pharma (NASDAQ:ENTA) reported its Q4 earnings results on Monday, November 20, 2023 at 04:01 PM.
Here's what investors need to know about the announcement.
Enanta Pharma beat estimated earnings by 33.5%, reporting an EPS of $-1.33 versus an estimate of $-2.0.
Revenue was down $1.39 million from the same period last year.
Last quarter the company beat on EPS by $0.47 which was followed by a 4.24% drop in the share price the next day.
Here's a look at Enanta Pharma's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -2.33 | -1.98 | -1.59 | -1.35 |
| EPS Actual | -1.86 | -1.79 | -1.39 | -1.27 |
| Revenue Estimate | 18.06M | 19.18M | 22.57M | 22.86M |
| Revenue Actual | 18.89M | 17.80M | 23.59M | 20.32M |
To track all earnings releases for Enanta Pharma visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ENTA
